Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Cambridge Biotech Startup Rubius Banks $120 Million, Hopes to Hire 60 New Staffers June 20, 2017 Celgene To Announce Second Quarter 2017 Results On July 27, 2017 July 4, 2017 Reata Pharmaceuticals, Inc. Announces First Quarter 2017 Financial And Operating Results May 10, 2017
Reata Pharmaceuticals, Inc. Announces First Quarter 2017 Financial And Operating Results May 10, 2017